A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer

By Samant R.S.   Dunscombe P.B.   Roberts G.H.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 3, 2003-05 ,pp. : 171-177

Elsevier

Access to resources Recommend Favorite

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

By Berger K.   Fischer T.   Szucs T.D.  

European Journal of Cancer, Vol. 34, Iss. 12, 1998-11 ,pp. : 1894-1901

Elsevier

Access to resources Recommend Favorite

Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

By Purmonen Timo T.   Päänkäälääinen Emma   Turunen Juha H. O.   Asseburg Christian   Martikainen Janne A.  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 344-352

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

By Norum J.   Olsen J. A.   Wist E. A.   Lønning P. E.  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

Locally Advanced Breast Cancer: Early Results of a Randomised Trial of Multimodal Therapy Versus Initial Hormone Therapy

By Willsher P.C.   Robertson J.F.R.   Chan S.Y.   Jackson L.   Blamey R.W.  

European Journal of Cancer, Vol. 33, Iss. 1, 1997-01 ,pp. : 45-49

Elsevier

Access to resources Recommend Favorite